This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-15. Anything still debated is marked as such rather than presented as settled.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
=== GPV / IIIa (GPV / IIa = integrin α5β1) === This is a heterodimer. Its α5 subunit is 36% identical to the GPIIb subunit. This complex is located mainly on endothelial cells but also on smooth muscle cells, macrophages and platelets. Its main function is in the adhesion of cells to the extracellular matrix components.
=== Bethlem myopathy 2 === (Collagen XII gene) See Bethlem myopathy 2 Clinical synopsis on OMIM: 616471 In Bethlem myopathy 2, there is phenotypic variability. In one family, the only notable finding on T1-weighted MR images (used to detect fatty infiltration) was atrophy of the rectus femoris muscles of the thigh, with the degree of atrophy matching the severity of the disease, but no fatty infiltration. In another family, only the more severely affected older patient showed significant abnormality, by having symmetrical fatty atrophy of the femoral quadriceps of the thigh, the adductor and medial gastrocnemius muscles of the calf; as well as asymmetrical fatty atrophy of the adductor longus of the thigh. No muscle hypertrophy was reported and the muscles of the patients without fatty atrophy appeared normal. Bethlem myopathy 2 also differs by including the possibility of scapula winging, pectus excavatum, stooped posture, kyphosis (hunchback), micrognathia, retrognathia, and a high-arched palate. Childhood muscle weakness improves in teen years, but muscle weakness returns by the third decade of life.
== Video game == To coincide with the film's release, Sony Pictures commissioned video game developer Black Widow Games to develop a promotional tie-in mod for the video game Half-Life titled Underworld: Bloodline. The mod was available on Sony Pictures' official website until the end of 2007. An asymmetric multiplayer FPS, the game tasks players with choosing between Vampires and Lycans, engaging in objective-based combat across urban maps. Each faction features distinct classes, weapons, and movement abilities, while gameplay revolves around capturing or defending Hybrid NPCs across four maps, blending mechanics inspired by Half-Life's mods Counter-Strike and Vampire Slayer. It is the only officially licensed Half-Life mod tied to a Hollywood movie.
Georgia joined the Iraq war as part of the United States-led coalition in August 2003. By 2008, Georgia had deployed 2,300 troops in Iraq, becoming the third largest contributor to the coalition forces in the Iraq War. In addition, the country provided a battalion of approximately 550 troops to the United Nations Assistance Mission in Iraq. All Georgian troops were withdrawn from Iraq amid the Russia–Georgia war in August 2008. Georgia suffered five fatal casualties in Iraq.
(2026) study the anatomy of ulna and femur or Sahelanthropus tchadensis, interpreted as indicative of presence of adaptations to bipedalism in spite of similarities in size and geometric morphometric shape to bones of chimpanzees. De Jager et al. (2026) study the frequency, position, and variability of cortical sulcal imprints in endocasts of extant chimpanzees and bonobos, providing a comparative resource for the studies of the brain evolution based on hominin fossils. Dunbar (2026) reevaluates data from the study of Deaner & Nunn (1999), finds evidence of changes in brain size following increases in body size in the evolution of primates but in a more complicated way that suggested by the original brain lag hypothesis, with an increase in body size followed by a progressively greater increase in brain size, and finds evidence of such evolution of brain and body size in hominins.
Sources: en.wikipedia.org
== Society and culture == The term was first used in the 14th century. A fistula plays a central role in William Shakespeare's play All's Well That Ends Well. An arteriovenous fistula is also a main plot point in Richard Fleischer's 1966 film Fantastic Voyage (screenplay by Harry Kleiner), sending the miniaturized submarine inside a patient's body on an unforeseen course.
=== Training volume === Training volume is commonly defined as sets × reps × load. That is, an individual moves a certain load for some number of repetitions, rests, and repeats this for some number of sets, and the volume is the product of these numbers. For non-weightlifting exercises, the load may be replaced with intensity, the amount of work required to achieve the activity. Training volume is one of the most critical variables in the effectiveness of strength training. There is a positive relationship between volume and hypertrophy. The load or intensity is often normalized as the percentage of an individual's one-repetition maximum (1RM). Due to muscle failure, the intensity limits the maximum number of repetitions that can be carried out in one set, and is correlated with the repetition ranges chosen. Depending on the goal, different loads and repetition amounts may be appropriate:
== Background == The elections were held less than a year after the July 1921 legislative elections, in which the Republican Liberal Party (PLR) had won a majority of votes. However, on 19 October 1921 ("the night of blood"), a military coup resulted in several republican figures being killed, including PLR prime minister António Granjo. On the night of blood, President António José de Almeida invested Manuel Maria Coelho as Prime Minister, but his government resigned on 3 November. On the same day, Carlos Maia Pinto became Prime Minister, but also resigned on 16 December. Francisco Cunha Leal then served as Prime Minister until the elections. The elections took place amidst instability and violence and were postponed four times before finally taking place on 29 January.
Chebulagic acid is a benzopyran tannin and an antioxidant that has many potential uses in medicine. It has been found to be immunosuppressive, hepatoprotective, and a potent alpha-glucosidase inhibitor, a human gut enzyme useful in diabetic studies. It has been shown to be active against Staphylococcus aureus and Candida albicans. It is found in the plants Terminalia chebula, T. citrina and T. catappa. It is formed from geraniin through a glutathione-mediated conversion.
== Early life == Daveigh Elizabeth Chase-Schwallier was born on July 24, 1990, in Las Vegas, Nevada, to Cathy Chase and John David Schwallier. She was young when her parents divorced. Each remarried, and she grew up with several half-siblings, including a younger half-brother named Cade. Chase later used her mother's maiden name professionally. She subsequently relocated with her mother to Albany, Oregon, where she performed in local talent shows and pageants. Her early vocal performances were centered on country music, for which she won a national vocal competition during her childhood. During a stay in Los Angeles, Chase began attending casting calls and booking minor roles, including national television advertising spots at age seven for the Campbell's Soup Company. Chase appeared in a regional theatrical production of the musical Utah! at the Tuacahn Amphitheatre in 1998, sharing the role of Norma Sanderson. She credited this stage experience with refining her live singing ability and performance presence.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.